Geneva, Switzerland, 10 August 2016 – ObsEva, a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced that Ernest Loumaye, MD, PhD, Co-Founder & Chief Executive Officer of ObsEva, will present a company overview at the 2016 Wedbush Pacgrow Healthcare Conference on Wednesday, August 17, 2016 at 1:20 p.m. ET at Le Parker Meridien in New York City.
About ObsEva
ObsEva is a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to birth. Between the ages of 20 and 50, millions of women worldwide suffer from reproductive health conditions that affect their quality of life and their ability to conceive or may lead to complications during pregnancy. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and efficacy profiles. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with multiple development programs focused on treating uterine fibroids, endometriosis, Assisted Reproductive Technology and preterm labor. ObsEva is supported by top-tier investors and a globally recognized board and is well-positioned to establish a leadership position in women’s reproductive therapeutics. For more information, please visit www.ObsEva.com.
Media Contact:
Liz Bryan
Spectrum
+1 (202) 955 6222
Company Contact:
Delphine Renaud
ObsEva, CEO Office
+41 22 552 1550
